Skip to content
sugarisadrug.com
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

Month: June 2026

2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study

June 21, 2026 by sugaradmin

Introduction and Objective: Metabolic Associated Steatotic Liver Disease (MASLD) frequently coexists with type 2 diabetes mellitus (T2DM) and obesity and represents a major unmet clinical need, particularly with respect to therapies that improve both hepatic and metabolic outcomes. Comparative data between saroglitazar (SARO) and dapagliflozin (DAPA) in MASLD are limited.Methods: A 24-week, prospective, multicenter, open-label, […]

Read More
DiabetesLeave a Comment on 2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study

2706-LB: Short Duration, High Risk: Poor Metabolic Profile Drives Complications More than Diabetes Duration

June 21, 2026 by sugaradmin

Introduction and Objective: Diabetes duration is considered a primary risk factor, yet some long-standing diabetics remain complication-free while recent-onset patients develop rapid damage. We investigated whether metabolic profile (triglycerides, BMI) could override traditional duration-complication relationships in community-based type 2 diabetes.Methods: Analysis of 400 T2DM patients stratified by duration (<5y n=142, 5-10y n=158, >10y n=100) and […]

Read More
DiabetesLeave a Comment on 2706-LB: Short Duration, High Risk: Poor Metabolic Profile Drives Complications More than Diabetes Duration

1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

June 21, 2026 by sugaradmin

Introduction and Objective: AT7687 is a novel GIP receptor (GIPR) peptide antagonist being developed for weight management and cardiometabolic disease. Cagrilintide is a dual amylin and calcitonin receptor (CTR) agonist with established weight-lowering efficacy. To assess the therapeutic potential of combining GIPR antagonism with amylin/CTR agonism, a chronic study was conducted in non-human primates (NHPs).Methods: […]

Read More
DiabetesLeave a Comment on 1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys

2704-LB: Screening Rates and Guideline-Directed Medical Therapy Use for Chronic Kidney Disease in People with Type 2 Diabetes

June 21, 2026 by sugaradmin

Introduction and Objective: Guideline-directed medical therapy (GDMT) improves outcomes in people with type 2 diabetes (T2D) and chronic kidney disease (CKD) but remains underused, possibly due to low CKD screening rates. This study evaluated screening and GDMT prescribing patterns in people with T2D with and without CKD.Methods: We performed a retrospective analysis of active patients […]

Read More
DiabetesLeave a Comment on 2704-LB: Screening Rates and Guideline-Directed Medical Therapy Use for Chronic Kidney Disease in People with Type 2 Diabetes

2159-P: Perceptions, Knowledge Gaps, and Support Needs Related to Gestational Diabetes Mellitus among Women Aged 20–49 Years: A Nationwide Survey

June 21, 2026 by sugaradmin

Introduction and Objective: Gestational diabetes mellitus (GDM) affects ~12% of pregnancies and is associated with maternal and offspring perinatal complications and long-term metabolic risk. We assessed GDM-related knowledge gaps, perceptions, and support needs among women aged 20-49 years to inform seamless support across preconception, pregnancy, and postpartum periods.Methods: A nationwide cross-sectional web survey included women […]

Read More
DiabetesLeave a Comment on 2159-P: Perceptions, Knowledge Gaps, and Support Needs Related to Gestational Diabetes Mellitus among Women Aged 20–49 Years: A Nationwide Survey

2703-LB: A Circulating microRNA Signature for Familial Risk of Type 2 Diabetes and Renal Failure

June 21, 2026 by sugaradmin

Introduction and Objective: Circulating microRNAs (miRNAs) regulate metabolic and inflammatory pathways and may reflect genetic risk of type 2 diabetes (T2D) and renal failure (RF), captured through family history. Whether circulating microRNAs capture familial risk better than clinical characteristics is currently unknown.Methods: This cross-sectional design assessed a discovery subset (n=81) from a historical 2×2 factorial […]

Read More
DiabetesLeave a Comment on 2703-LB: A Circulating microRNA Signature for Familial Risk of Type 2 Diabetes and Renal Failure

2154-P: Second-Line Antidiabetic Exposure in Early Pregnancy and Risk of Spontaneous Abortion: A Nationwide Cohort Study

June 21, 2026 by sugaradmin

Introduction and Objective: Most second-line antidiabetic agents are contraindicated during pregnancy; however, unintended exposure during early gestation is common. We assessed the risk of spontaneous abortion (SAB) associated with the continued use of second-line antidiabetics during early pregnancy.Methods: Using the National Health Information Database of Korea from 2012 to 2023, we identified pregnant women with […]

Read More
DiabetesLeave a Comment on 2154-P: Second-Line Antidiabetic Exposure in Early Pregnancy and Risk of Spontaneous Abortion: A Nationwide Cohort Study

2702-LB: Urinary Post-translationally Modified Fetuin-A Predicts Renal Outcomes Independent of Albuminuria and eGFR in Type 2 Diabetes and CKD: CREDENCE Analysis

June 21, 2026 by sugaradmin

Introduction and Objective: Albuminuria incompletely predicts diabetic kidney disease (DKD) progression. Urinary post-translationally modified Fetuin-A (uPTM-FetA) reflects kidney stress-related pathophysiology. We evaluated whether uPTM-FetA predicts renal outcomes independent of albuminuria and eGFR in CREDENCE participants with type 2 diabetes and CKD.Methods: Baseline urine from 1,466 participants was analyzed for uPTM-FetA. Associations with UACR and eGFR […]

Read More
DiabetesLeave a Comment on 2702-LB: Urinary Post-translationally Modified Fetuin-A Predicts Renal Outcomes Independent of Albuminuria and eGFR in Type 2 Diabetes and CKD: CREDENCE Analysis

3 Studies Link Diet, Fitness, Multivitamins to Slower Aging

June 21, 2026 by sugaradmin

Share on PinterestStudies show that diet, fitness, and multivitamins may help slow the aging process. Image Credit: Maria Sher/Stocksy Research suggests that taking a multivitamin every day may help slow the signs of biological aging. A recent study found that higher midlife cardiorespiratory fitness levels may be associated with a longer life span. According to […]

Read More
Health NewsLeave a Comment on 3 Studies Link Diet, Fitness, Multivitamins to Slower Aging

1462-P: Hyperbaric Oxygen Therapy as an Adjunct to Standard Medical and Surgical Care for Diabetic Foot Ulcers: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

June 21, 2026 by sugaradmin

Introduction and Objective: Diabetic foot ulcers (DFUs) remain a major complication of diabetes associated with impaired healing and amputation risk. Hyperbaric oxygen therapy (HBOT) has been proposed as an adjunctive treatment, but evidence continues to evolve. The objective of this updated systematic review and meta-analysis is to analyze the efficacy of hyperbaric oxygen for the […]

Read More
DiabetesLeave a Comment on 1462-P: Hyperbaric Oxygen Therapy as an Adjunct to Standard Medical and Surgical Care for Diabetic Foot Ulcers: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Posts navigation

Older posts

Recent Posts

  • 2474-P: Comparable Hepatic Benefits with Differential Effects on Triglycerides and Glycemic Control: A 24-Week Prospective Study
  • 2706-LB: Short Duration, High Risk: Poor Metabolic Profile Drives Complications More than Diabetes Duration
  • 1713-P: AT7687, a Novel GIP-Receptor Antagonist, Combined with Cagrilintide, Leads to Robust Weight Loss and Substantial Improvements in Insulin Sensitivity and Body Composition in Obese Insulin-Resistant Monkeys
  • 2704-LB: Screening Rates and Guideline-Directed Medical Therapy Use for Chronic Kidney Disease in People with Type 2 Diabetes
  • 2159-P: Perceptions, Knowledge Gaps, and Support Needs Related to Gestational Diabetes Mellitus among Women Aged 20–49 Years: A Nationwide Survey

Recent Comments

  • A WordPress Commenter on SUCROSE: “PURE” ENERGY AT A PRICE

Archives

  • June 2026
  • May 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • November 2024
  • October 2024
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • May 2017

Categories

  • Celebrity Health
  • Diabetes
  • Food Choices
  • Fructose
  • General Sugar
  • Glucose
  • Health News
  • Insulin
  • Mental Health
  • Natural Unrefined Sugar
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Sucrose
  • Sugar Science

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
  • Home
  • Diabetes
  • Health News
  • General Sugar
  • Food Choices
  • Insulin
  • Mental Health
  • Stop Eating Sugar
  • Stop Killing Yourself
  • Fructose
  • Sugar Science

© 2026 Sugar is a DRUG | Sugar Addiction Awareness